If you get migraines, you already know they are not headaches. They are neurological events with an opening act, a main show, and sometimes a full day of aftermath. So when customers ask whether CBD helps with migraines, we want to be careful, because desperate people are easy to sell to and the research here is thinner than almost any other CBD topic we write about.
Here is the short version: there is not a single published clinical trial of CBD by itself for migraine. Everything we know comes from studies of whole cannabis, THC and CBD combinations, surveys, and one interesting theory. That is the honest starting point.
The endocannabinoid deficiency idea
The most interesting thread comes from Dr. Ethan Russo, who proposed back in the early 2000s that some conditions, migraine among them, might involve a shortfall in the body’s own endocannabinoid system. The supporting evidence is real but modest: studies have found lower levels of anandamide, one of the body’s natural cannabinoid molecules, in the spinal fluid of people with chronic migraine. Anandamide appears to influence serotonin signaling and pain processing in ways that overlap with how migraines behave.
It is a tidy theory. It is also still a theory. Low anandamide in migraine patients could be a cause, an effect, or a coincidence, and the studies were small. But it explains why researchers keep circling back to cannabinoids for this condition.
What the actual studies used
The most cited clinical data came out of a 2017 presentation to the European Academy of Neurology. Italian researchers gave chronic migraine patients a 200 mg daily dose of a THC and CBD combination for three months and found it reduced pain about as well as amitriptyline, a standard preventive medication, cutting attacks by roughly 40 percent in some measures. Worth noting: that was conference data, the compound was mostly THC with CBD alongside, and 200 mg is a large dose.
Beyond that, there are surveys. A 2020 study using data from a migraine tracking app found that people who used cannabis reported shorter, less severe attacks, and other patient surveys point the same direction. Survey data is where placebo effects and hopeful memories go to multiply, so treat it as a signal for future research, not proof.
For CBD alone, at the doses in gummies and oils, we simply do not have trial data. Anyone who tells you otherwise is selling something.
If you want to try it anyway
We understand the math. Migraines are miserable, CBD is low-risk for most people, and waiting for perfect research can take decades. If you experiment, do it in a way that produces usable information.
- Track your attacks for a month before you start, then keep tracking. Frequency, duration, severity. Migraine patterns vary so much that memory alone will fool you.
- Decide whether you are testing prevention (a daily dose) or rescue (a dose at onset). The Italian data, for what it is worth, was a daily preventive approach.
- Change nothing else during the test. New pillow, new diet, and new CBD in the same month tells you nothing.
- Keep your prescribed treatment. Triptans, CGRP blockers, and preventives exist because they passed the trials CBD has not. CBD is an addition to discuss with your neurologist, not a substitute.
- Check interactions first. CBD shares liver enzymes with many medications, including some used for migraine prevention. Your pharmacist can check your specific list in minutes.
One more caution: some people find strong smells and certain substances can themselves be migraine triggers. Introduce anything new at a low dose on a day you can afford to lose, just in case your brain files it under enemy.
Where this leaves us
Migraine is probably the condition where the gap between customer interest and actual CBD evidence is largest. The endocannabinoid theory is genuinely interesting, the combination studies are suggestive, and the CBD-alone data does not exist yet. We would love to write a more confident post in five years. Until then, if you try it, be your own careful experiment, and keep your neurologist in the loop.